Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

'Fraud' Accusations Vex Valeant, Slam 'Specialty' Shares

This article was originally published in Scrip

Executive Summary

It's unclear whether it was simply another example of Valeant Pharmaceuticals International Inc.'s inability to clearly communicate or there's some actual wrongdoing going on, but the company's shares took a beating on Oct. 21, with the stock freefalling 40% – a walloping that spread to other drug makers in the sector.


Related Companies